EZH2 and nonpapillary renal cell carcinoma: Modulating EZH2 expression or activity has been reported to suppress the phosphorylation of certain receptor tyrosine kinase inhibitors and restore the antitumor effects of sunitinib in models of acquired or intrinsically resistant ccRCC [59].